submit to the journals

Colorectal Cancer Journal Articles, Videos And Insights

Colorectal Cancer:FEATURED Articles

flipper_slider

Colorectal Cancer: Latest Articles

Colorectal Cancer: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
ESMO 2018 – Immunotherapy may Become new First-line Treatment in some Metastatic Colorectal Cancers Katrina Mountfort
Senior Medical Writer, Touch Medical Media, Goring-on-Thames, UK

Colorectal Cancer:FEATURED VIDEOS

Editor's choice

Editorial board member John L Marsahll from The Ruesch Center for the Cure of GI Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center in Washington, DC discusses unmet needs and major advances in the treatment of colorectal cancers, and how PARP inhibitors may play a role in treatment strategies in the near future. 1. What are the major unmet needs in the treatment of colorectal cancer? (0:11) 2. What have been the most important advances in colorectal cancer research in the past year? (0:41) 3. How is personalized medicine impacting the treatment of patients with colorectal cancer? (1:24) 4. What is the rationale for the use of PARP inhibitors in colorectal cancer? (2:14) Speaker disclosures: John L Marshall has nothing to disclose in relation to this video interview. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Chinthalapally V Rao from the University of Oklahoma Health Sciences Center, Oklahoma City, OK, US, talks to us about the protective role of aspirin and other NSAIDs in colorectal cancer. 1. What is currently known about the protective role of aspirin and other NSAIDs in colorectal cancer? (0:08) 2. Could you tell us a little about your recent study investigating intermittent dosing regimens of naproxen and aspirin in colon adenoma? (0:30) 3. How often and for how long should naproxen and aspirin be taken to achieve a protective effect? (1:18) 4. What are the limitations of this approach? (1:41) 5. What future studies are planned? (2:15) Speaker disclosures: Chinthalapally V Rao has nothing to disclose in relation to this video interview. Filmed at the American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL, US, April 14–18, 2018. NSAIDS = non-steroidal anti-inflammatory drugs

Colorectal Cancer:Latest Videos

Video List based on Category on Node Page

Latest Videos

In this interview at ESMO 2018, Marc Peeters talks to touchONCOLOGY about colorectal cancer tumour location and biomarkers. He explains that left-sided cancers have a better prognosis and suggests some possible reasons for this. Dr Peeters also discusses how the use of biomarkers has developed in...
The Poseidon study was a phase I/II study in second-line KRAS mild-type metastatic colorectal cancer (mCRC) that did not meet its endpoint of progression-free survival, but did suggest a subgroup of patients with high alpha v beta 6 integrin expression who would benefit from abituzumab. In this...
Editorial board member John L Marsahll from The Ruesch Center for the Cure of GI Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center in Washington, DC discusses unmet needs and major advances in the treatment of colorectal cancers, and how PARP inhibitors...
Chinthalapally V Rao from the University of Oklahoma Health Sciences Center, Oklahoma City, OK, US, talks to us about the protective role of aspirin and other NSAIDs in colorectal cancer. 1. What is currently known about the protective role of aspirin and other NSAIDs in colorectal...
Marwan Fakih discusses the implications of primary tumour location on biological therapy in metastatic colorectal cancer.
Part 2 of 2 – Dr Marc Peeters, from our European Editorial Board, explains the move from treating patients with BRAF-targeting drugs, to using combination therapy to target the EGFR pathway in BRAF-mutant mCRC. He also discusses the BEACON CRC study, which uses this combination of binimetinib,...

LATEST TWEETS

Conference Highlights